The Genomic Test Demonstrated 100 Percent Sensitivity and 100 Percent Specificity for MTC The Afirma MTC Classifier is included as part of the Afirma testing offering on all orders for patients with ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at the 2023 American Thyroid Association (ATA) Annual Meeting demonstrate the type ...
Please provide your email address to receive an email when new articles are posted on . Researchers obtained thyroid FNA samples from Beth Israel Deaconess Medical Center that were submitted for ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that new data from the Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary ...
San Diego-based Dexcom Inc., is the target of a class action lawsuit in U.S. district court over the company’s G7 continuous glucose monitors, an action which ...
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that Cigna, one of ...
Company also introduces research-use-only Afirma Genomic Resource for Intelligent Discovery (GRID) platform for additional insights into thyroid nodules and cancer “These ATA presentations underscore ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback